Proactive Investors - Run By Investors For Investors

Fevertree Drinks shares go flat after company’s co-founders sell off more stock to satisfy institutional demand

After the market close on Monday, the AIM-listed firm said the two founders intended to sell in aggregate approximately 2mln ordinary shares in the company
Fevertree drinks
However, due to significant institutional demand, the selling shareholders actually disposed of 3mln Fevertree shares

Fevertree Drinks PLC (LON:FEVR) saw its shares go flat on Tuesday after the mixer drinks company’s co-founders, Charles Rolls and Tim Warrillow - its non-executive deputy chairman and chief executive officer respectively – sold off more stock.

After the market close on Monday, the AIM-listed firm said the two founders intended to sell in aggregate approximately 2mln ordinary shares in the company via an accelerated bookbuild placing in response to demand from institutional investors.

READ: Fevertree fizzes to fresh all-time high as it upgrades full-year guidance once again

However, due to significant institutional demand, the selling shareholders actually disposed of 3mln Fevertree shares, representing approximately 2.6% of the group’s issued share capital.

Fevertree said the shares were sold at a price of 3,450p each in the placing, which was managed by Investec Bank acting as sole bookrunner.

In lunchtime trading, Fevertree shares were 2.8% lower at 3,578p.

The company added that it was not a party to the placing and, therefore, will not receive any proceeds.

It noted that Rolls sold 2mln ordinary shares, taking his holding down to around 8.2mln shares or about 7.1% of the company, while Warrillow sold 1mln ordinary shares, reducing his holding to about 5.4mln shares or approximately a 4.7% stake.

Back in March, Rolls had sold 3mln Fevertree shares – double the initial intention for a 1.5mln share sale – via a placing to investors at a price of 2,750p per share, again due to significant institutional demand.

Fevertree shares fizzed up to a fresh all-time high at the end of July as the posh tonic maker upgraded its full-year guidance once again following a jump in first-half revenue and earnings.

For the six months ended June 30 2018, Fevertree reported a 45% leap in revenue to £104.2mln (H1 17: £71.9mln), while adjusted underlying earnings (EBITDA) climbed by 35% to £34.0mln (H1 17: £25.2mln).

View full FEVR profile View Profile

Fevertree Drinks Timeline

Related Articles

drainpipes
May 23 2019
Company is looking for more acquisitions after integration of Metro Rod
medical imaging graphic
June 13 2019
Here we take a closer look at the imaging and diagnostics firm IQ-AI
H&T
May 21 2019
H&T investing in digital offeringProfits gain in 2018Outlook upbeat as strategy pays off

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use